Completed PHASE2 INTERVENTIONAL 8-arm NCT00170612

Pneumococcal Vaccination of Fiji Infants

A Single-Blind Open-Label Randomized Phase II Study of the Safety, Immunogenicity and Impact on Pneumococcus (Pnc) Carriage of the Pnc Vaccination Regimens Combining 1, 2, or 3 Doses of 7-Valent Pneumococcal Conjugate Vaccine (PCV) in the First 4 Months of Life Followed by a Single Dose of 23-Valent Pneumococcal Polysaccharide Vaccine (PPS) at 12 Months of Age

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions Pneumococcal Infections

Interventions Pneumovax 23 Prevnar

Updated 5 times since 2017 Last updated: Oct 20, 2008 Started: Nov 30, 2005 Primary completion: Jan 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00170612, this PHASE2 trial focuses on Pneumococcal Infections and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 5 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)
University of Melbourne

Data source: University of Melbourne

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suva, Fiji